Denali Therapeutics Inc. (NASDAQ:DNLI) Director Steve E. Krognes Sells 30,000 Shares

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $22.12, for a total value of $663,600.00. Following the completion of the sale, the director now owns 34,404 shares of the company’s stock, valued at $761,016.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Denali Therapeutics Stock Performance

Denali Therapeutics stock opened at $21.30 on Thursday. Denali Therapeutics Inc. has a 12 month low of $14.56 and a 12 month high of $30.79. The stock’s 50 day simple moving average is $19.80 and its two-hundred day simple moving average is $19.28.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.01. During the same quarter last year, the business posted ($0.80) EPS. As a group, equities research analysts expect that Denali Therapeutics Inc. will post -2.78 earnings per share for the current year.

Institutional Investors Weigh In On Denali Therapeutics

Hedge funds have recently modified their holdings of the company. Alps Advisors Inc. boosted its position in Denali Therapeutics by 0.8% during the third quarter. Alps Advisors Inc. now owns 101,400 shares of the company’s stock worth $2,092,000 after purchasing an additional 780 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in Denali Therapeutics by 48.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock worth $53,000 after acquiring an additional 807 shares in the last quarter. CWM LLC raised its position in Denali Therapeutics by 216.7% during the fourth quarter. CWM LLC now owns 2,011 shares of the company’s stock worth $43,000 after acquiring an additional 1,376 shares during the period. Assetmark Inc. lifted its holdings in Denali Therapeutics by 65.3% during the fourth quarter. Assetmark Inc. now owns 3,550 shares of the company’s stock valued at $76,000 after purchasing an additional 1,402 shares in the last quarter. Finally, Swiss National Bank grew its position in shares of Denali Therapeutics by 0.7% in the first quarter. Swiss National Bank now owns 218,200 shares of the company’s stock valued at $4,477,000 after purchasing an additional 1,500 shares during the period. 92.92% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on DNLI. HC Wainwright restated a “buy” rating and issued a $95.00 price target on shares of Denali Therapeutics in a report on Wednesday, May 8th. Wedbush reduced their price objective on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, May 8th. Stifel Nicolaus cut their price target on Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating on the stock in a report on Wednesday, May 8th. Finally, UBS Group decreased their price objective on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, April 9th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $40.22.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.